Get the Stockscreener App
6.7356
1.67%
-0.1144
Coya Therapeutics Inc stock is traded at $6.7356, with a volume of 21,625.
It is down -1.67% in the last 24 hours and down -7.22% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.85
Open:
$6.89
24h Volume:
21,625
Relative Volume:
0.30
Market Cap:
$113.05M
Revenue:
-
Net Income/Loss:
$-12.36M
P/E Ratio:
-5.0777
EPS:
-1.3265
Net Cash Flow:
$-11.39M
1W Performance:
-8.61%
1M Performance:
-7.22%
6M Performance:
-22.40%
1Y Performance:
+32.85%
1-Day Range:
$6.718
$6.94
1-Week Range:
$6.12
$7.44
52-Week Range:
$4.40
$10.69
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Coya Therapeutics Inc Stock (COYA) Latest News
Long Term Trading Analysis for (COYA) - Stock Traders Daily
Arun Swaminathan assumes new role as chief executive officer of Coya Therapeutics - pharmabiz.com
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress By Investing.com - Investing.com South Africa
Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Significant Increase in Short Interest - MarketBeat
Coya Therapeutics appoints new CEO amid Alzheimer's trial progress - Investing.com
Coya Therapeutics Promotes Arun Swaminathan, Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - StockTitan
Coya Therapeutics announces executive changes - Investing.com India
Coya Therapeutics Announces Leadership Change and New CEO - TipRanks
Coya Therapeutics announces executive changes By Investing.com - Investing.com UK
Coya Therapeutics On Developing A Combination Biologic - BioProcess Online
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics reports promising Alzheimer's trial results By Investing.com - Investing.com South Africa
See the Impacts of Waco’s Walk to End Alzheimer’s - AOL
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya stock tumbles 23% on mixed results from Alzheimer's study - MSN
Coya stock tumbles 23% on mixed results from Alzheimer's study (NASDAQ:COYA) - Seeking Alpha
Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth - Simply Wall St
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters
Coya Therapeutics reports promising Alzheimer's trial results - Investing.com India
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan
When (COYA) Moves Investors should Listen - Stock Traders Daily
Coya Therapeutics secures $10 million in private placement By Investing.com - Investing.com Australia
Coya Therapeutics Announces $10.0 Million Private Placement - citybiz
Coya Therapeutics Shares Rise 9% After $10 Million Private Placement - MarketWatch
Coya Therapeutics secures $10 million in private placement - Investing.com
Coya Therapeutics Announces $10M Private Placement to Advance Pipeline - TipRanks
Regulatory T-Cell (Tregs) Therapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Tips for preventing or delaying dementia - AOL
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100 - citybiz
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic - openPR
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, Latest FDA, EMA, and PMDA Approvals | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO - Barchart
How the (COYA) price action is used to our Advantage - Stock Traders Daily
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update - MarketBeat
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure - Yahoo Finance
(COYA) Proactive Strategies - Stock Traders Daily
INNOVATIONMAP EMAILS ARE AWESOME - InnovationMap
Coty Inc. (NYSE:COTY) Shares Sold by Thrivent Financial for Lutherans - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Rhumbline Advisers - Defense World
MQS Management LLC Sells 18,446 Shares of Coty Inc. (NYSE:COTY) - Defense World
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks - Nasdaq
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
COYA 302 combination therapy tames brain inflammation in mice - Parkinson's News Today
HC Wainwright Comments on Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA) - MarketBeat
Play it back: Houston therapeutics co. sees momentum with expanded treatment opportunities - InnovationMap
CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors - Business Wire
Coya Therapeutics reports potential Parkinson's treatment breakthrough - Investing.com
Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright - MarketBeat
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):